$BHVN

Biohaven Ltd. (NYSE:BHVN) presented preclinical data for BHV-1420, a drug candidate for kidney disease, at the American Society of Nephrology Kidney Week 2026. The data showed promising results in tests and mouse models, targeting autoantibodies in membranous nephropathy. The company is exploring partnerships for its nephrology franchise, which includes BHV-1400 for IgA nephropathy. BHV-1420 is still in preclinical development.

Biohaven's experimental drug BHV-1420 showed promising results in lab tests, reducing 88% of anti-PLA2R-positive patient samples below the clinical threshold. The drug, designed to target kidney disease, achieved >90% depletion of circulating antibodies in a mouse model. Biohaven licensed the technology from Yale University.

RBC Capital kept its Sector Perform rating on Biohaven with a $22 price target, suggesting a 49.8% upside from the Oct 22 close. The target is based on positive pipeline developments, notably with the drug troriluzole, but RBC remains cautious due to regulatory and clinical risks.

Biohaven Ltd.'s average stock price target increased from $24.42 to $24.92, with a range of $10 to $48, implying 112% upside. 14 analysts maintain a 'Buy' consensus, with 10 Buys, 3 Holds, and 1 Sell.

Biohaven (BHVN) +31% after FDA accepted resubmitted drug application for spinocerebellar ataxia. Korro Bio (KRRO) +25% on positive preclinical results for AATD treatment. Actinium (ATNM) +18% with initial Phase 1 data for prostate cancer radiotherapy. Vicore (VCRE) +16% after passing IPF trial futility analysis.

Baird raised Biohaven Pharma's (BHVN) price target to $48 from $42, citing NDA acceptance for Vyglxia. The stock is up 2.8% over the past week. Biohaven also secured an $80M licensing deal with Ono Pharmaceuticals. The company faces FDA clinical holds on BHV-7000 and opakilim programs, but current patient dosing continues.

Biohaven Ltd. shares rose 25% after the FDA accepted its resubmitted drug application for troriluzole in spinocerebellar ataxia. The FDA considers the resubmission complete and set a user fee goal date for Q1 2027, with an advisory committee meeting planned.

Biohaven Ltd. (BHVN) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program. The FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia (troriluzole) in SCA has been accept

Biohaven has licensed its MoDE pan IgG degrader portfolio to Ono Pharmaceutical for $80M upfront, with 20% royalties on net sales in the licensed territories. Ono will lead development and commercialization in Japan, South Korea, Taiwan, and ASEAN countries, while Biohaven retains rights outside the territory.

Biohaven Ltd. (BHVN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease October 8, 2026 • Ono will obtain an exclusive license to develop and commercialize